View Document Preview and Link Document Date: 2012-04-03 12:17:58 Open Document File Size: 30,53 KB Share Result on Facebook
Company Regenerative Medicine / All Wales Medicine Strategy Group / Company’s Specialty Pharmaceuticals / Shire Pharmaceuticals Ltd / Shire plc. / Human Genetic Therapies / Firazyr / / Continent Europe / / Country United Kingdom / Scotland / Ireland / Wales / / / Facility University Hospital Wales / / IndustryTerm biopharmaceutical / manufacturing / / MedicalCondition hives / angioedema swellings / dysfunction / HAE / itchiness / allergic angioedema / C1-esterase inhibitor deficiency / hereditary angioedema / C1 esterase inhibitor deficiency / acute hereditary angioedema attacks / Hereditary / C1-esterase-inhibitor deficiency / deficit hyperactivity disorder / skin irritation / erythema / itching / pain / unstable angina pectoris / rare genetic disease / angioedema / allergic reactions / angioedemas / acute ischaemic heart disease / gastrointestinal diseases / / Organization University Hospital Wales / European Commission / European Union / NHS / Securities and Exchange Commission / / Person Janis Clayton / Stephen Jolles / Ann Allergy / Ann Price / Eric Rojas / / / Position mediator / physician / Consultant / VP & General Manager / Representative / specialist physician / Private / / Product INH / / Technology regenerative medicine / / URL www.shire.com / www.haeuk.org / / SocialTag 
Press Release www.shire.com AWMSG and SMC recommends/accepts FIRAZYR® (icatibant) as an option for the symptomatic treatment of acute attacks of Hereditary Angioedema (HAE) in adults